Glioblastoma Clinical Trials in Boston, MA

Glioblastoma Clinical Trials in Boston, MA

View the best 10 glioblastoma medical studies in Boston, Massachusetts. Access promising new therapies by applying to a Boston-based Glioblastoma clinical trial.

Trials in Boston, Massachusetts

Here are the top 10 medical studies for glioblastoma in Boston, Massachusetts

Image of START Midwest, LLC in Grand Rapids, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Image of Investigation Site in Newark, United States.

IGV-001 +2 More

Cell Immunotherapy

Recruiting0 awardsPhase 2
This trial will compare a new treatment for glioblastoma to placebo to see if it extends survival.
Image of Massachusetts General Hospital in Boston, United States.

Temozolomide +2 More

Alkylating Agent

Recruiting1 awardPhase 2
This trial is testing a combination of three drugs to treat brain tumors that have come back after previous treatments. The drugs help the immune system attack the tumor, stop the tumor cells from repairing themselves, and prevent them from growing. About 66-78 people will participate in this study.
Image of Massachusetts General Hospital in Boston, United States.

Personalized NeoAntigen Vaccine +1 More

Cancer Vaccine

Recruiting1 awardPhase 1
This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.
Image of Children's Hospital Los Angeles in Los Angeles, United States.

BGB-290 +1 More

PARP Inhibitor

Recruiting1 awardPhase 1
This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.
Image of Brigham and Women's Hospital in Boston, United States.

Cemiplimab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing the safety and effectiveness of combining two drugs, ASP8374 and cemiplimab, for people with recurrent brain cancer. The study aims to find the best dose and see if the combination helps before surgery. The drugs work by boosting the immune system to fight cancer cells. Cemiplimab has been previously tested in combination with other treatments for severe cancers.
Image of Yale University in New Haven, United States.

AB154 +1 More

Monoclonal Antibodies

Recruiting0 awardsPhase < 1
This trial is testing a new combination of drugs to treat glioblastoma, a type of brain cancer. The trial is divided into two groups, with the first group receiving the new combination of drugs to test for safety and the second group receiving the new combination of drugs as well as surgery.
Image of Illinois CancerCare-Bloomington in Bloomington, United States.

Atezolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.
Image of Vidant Health in Greenville, United States.

GammaTile radiation therapy implantation +3 More

Brachytherapy

Recruiting3 awardsPhase 4
This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.
Image of University of Alabama at Birmingham in Birmingham, United States.

Temozolomide +1 More

Alkylating agents

Recruiting1 awardPhase 2
This trial is testing a new drug called OKN-007 combined with a chemotherapy drug, temozolomide, in patients whose brain cancer has returned after standard treatments. OKN-007 may help reduce tumor growth and make the chemotherapy more effective. Temozolomide is effective in treating malignant brain tumors.

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' ā€” so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back ā€” in general, verified trials respond to patients within a few days.